1-(3,5-Dimethylpiperidino)-2-methyl-1-propanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(3,5-Dimethylpiperidino)-2-methyl-1-propanone
• 英文别名: 1-(3,5-dimethylpiperidin-1-yl)-2-methylpropan-1-one
• 化学式: C₁₁H₂₁NO
• mdl: MFCD01214209
• 分子量: 183.29
• InChiKey: UGPMWMKPQONUHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140329798A1

  公开（公告）日：2014-11-06

  Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included

  本发明公开了式（I）的取代环丙基化合物及其药学上可接受的盐，用于治疗或预防2型糖尿病和类似疾病。该化合物是G蛋白偶联受体GPR-119的激动剂，因此在药物组合物和治疗方法中也有用途。
• Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
  申请人：AMGEN INC.

  公开号：US10246429B2

  公开（公告）日：2019-04-02

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 and R10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.

  本发明提供了一类可用于调节β-分泌酶（BACE）活性的新型化合物。这些化合物具有通式 I：其中式 I 中的变量 A4、A5、A6、A7 和各变量 Ra、Rb、R1、R2、R3、R8 R9 和 R10 独立地在本文中定义。本发明还提供了包含本发明化合物的药物组合物，以及本发明化合物和组合物用于治疗因 BACE 的生物活性导致的与 Aβ 斑块形成和沉积有关的疾病和/或病症的用途。此类 BACE 介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病等。
• Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]
  申请人：Phenex Pharmaceuticals AG

  公开号：US10301272B2

  公开（公告）日：2019-05-28

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了孤儿核受体RORy的调节剂，以及通过向人类或有需要的哺乳动物施用这些新型RORy调节剂来治疗RORy介导的疾病的方法。具体地说，本发明提供了式(1)、(1′)、(100)、(100′)、(200)和(200′)的含羧酰胺或磺酰胺的环状化合物及其对映体、非对映体、同系物、/V-氧化物、溶剂和药学上可接受的盐。
• VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
  申请人：AMGEN INC.

  公开号：US20180222876A1

  公开（公告）日：2018-08-09

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 7 , and each of R a , R b , R 1 , R 2 , R 3 , R 8 R 9 and R 10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.
• US9018224B2
  申请人：——

  公开号：US9018224B2

  公开（公告）日：2015-04-28